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Summary
 
Murine V
 
a
 
14 natural killer T (NKT) cells are thought to play a crucial role in various immune
responses, including infectious, allergic, and autoimmune diseases. Because V
 
a
 
14 NKT cells
produce large amounts of both interleukin (IL)-4 and interferon (IFN)-
 
g
 
 upon in vivo stimula-
tion with a specific ligand, 
 
a
 
-galactosylceramide (
 
a
 
-GalCer), or after treatment with anti-CD3
antibody, a regulatory role on helper T (Th) cell differentiation has been proposed for these
cells. However, the identity of the cytokine produced by V
 
a
 
14 NKT cells that play a domi-
 
nant role on the Th cell differentiation still remains controversial. Here, we demonstrate by
using V
 
a
 
14 NKT-deficient mice that V
 
a
 
14 NKT cells are dispensable for the induction of an-
tigen-specific immunoglobulin (Ig)E responses induced by ovalbumin immunization or 
 
Nip-
postrongylus brasiliensis 
 
infection. However, upon in vivo activation with 
 
a
 
-GalCer, V
 
a
 
14 NKT
cells are found to suppress antigen-specific IgE production. The suppression appeared to be IgE
specific, and was not detected in either V
 
a
 
14 NKT– or IFN-
 
g
 
–deficient mice. Consistent with
these results, we also found that ligand-activated V
 
a
 
14 NKT cells inhibited Th2 cell differenti-
ation in an in vitro induction culture system. Thus, it is likely that activated V
 
a
 
14 NKT cells
exert a potent inhibitory effect on Th2 cell differentiation and subsequent IgE production by
producing a large amount of IFN-
 
g
 
. In marked contrast, our studies have revealed that IL-4
produced by V
 
a
 
14 NKT cells has only a minor effect on Th2 cell differentiation.
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V
 
a
 
14 natural killer T (NKT)
 
1
 
 cells constitute a novel
lymphoid lineage distinct from T, B, or NK cells in
the mouse immune system. V
 
a
 
14 NKT cells are character-
ized by the coexpression of NK1.1 NK receptor and a sin-
gle invariant antigen receptor encoded by V
 
a
 
14 and J
 
a
 
281
segments (1, 2) in association with a highly skewed set of
V
 
b
 
s, mainly V
 
b
 
8.2 (3–9). The invariant V
 
a
 
14/V
 
b
 
8.2 re-
ceptor appears not to be expressed on conventional T cells
and its expression is essential for V
 
a
 
14 NKT cell develop-
ment (10–12). In fact, deletion of J
 
a
 
281 gene segment re-
sults in the selective loss of V
 
a
 
14 NKT cell development
(NKT-KO mice) (12). Furthermore, transgenic V
 
a
 
14/
V
 
b
 
8.2 receptor expressed in recombination-activating gene
1–deficient (RAG-1
 
2/2
 
) mice leads to the development of
V
 
a
 
14 NKT cells but not of other lymphoid populations
(V
 
a
 
14 NKT mice) (13). Taken together, these findings
strongly indicate that V
 
a
 
14/V
 
b
 
8.2 is a unique antigen re-
ceptor for V
 
a
 
14 NKT cells but not for conventional T
cells. The NKT cell development was largely inhibited in
 
b
 
2-microglobulin–deficient mice (14–16) and CD1d-defi-
cient mice (17–19). These results suggested the existence of
CD1d-dependent positive selection of V
 
a
 
14-expressing
immature NKT cells during their development. Recently,
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
-GalCer, 
 
a
 
-galactosylceramide; B6,
C57BL/6; Nb, 
 
Nippostrongylus brasiliensis
 
; NKT cells, natural killer T cells;
NKT-KO mice, V
 
a
 
14 NKT-deficient mice; PCA, passive cutaneous
anaphylaxis; RAG
 
2/2
 
, recombination-activating gene 1–deficient; RT,
reverse transcriptase; V
 
a
 
14 NKT mice, RAG
 
2/2
 
 V
 
a
 
14Tg V
 
b
 
8.2Tg
mice. 
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a ligand for the invariant V
 
a
 
14 NKT cell receptor has been
identified as a glycolipid, 
 
a
 
-galactosylceramide (
 
a
 
-GalCer,
KRN7000), which is presented by CD1d (13). In addition,
recent reports also suggest that glycosylphosphatidylinosi-
tol-anchored proteins may stimulate NKT cells in a CD1d-
dependent manner (20, 21).
Mouse CD4
 
1
 
 helper T cells can be divided into two dis-
tinct subpopulations on the basis of their cytokine produc-
tion patterns, and are designated as type 1 (Th1) and type 2
(Th2) cells (22). Th1 cells produce IL-2, IFN-
 
g
 
, and TNF-
 
b
 
,
whereas Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10,
and IL-13 (23–26). The development of Th1 and Th2 cells
is central to the diversity of CD4 T cell–dependent im-
mune responses in infectious, allergic, and autoimmune
diseases (23, 24). Th1 cells mediate delayed-type hypersen-
sitivity and organ-specific autoimmune diseases, whereas
Th2 cells are involved in the development of allergies and
the defense against extracellular microorganisms.
Th1 and Th2 cells are thought to be differentiated from
a common precursor (23) and the direction of Th cell dif-
ferentiation into Th1 and Th2 cells is dependent on exoge-
nous cytokines present during the primary antigenic stimu-
lation of naive T cells. It is now well documented that the
potent inducer of Th1 is IL-12 (27–30). Th1 cell differenti-
ation is inhibited in mice deficient for p40, a subunit of IL-
12 receptor (31), and also in mice deficient for STAT4, a
downstream signaling molecule of IL-12 receptor (32, 33).
IFN-
 
g
 
, which is reported to induce IL-12 secretion from
various antigen presenting cells (34, 35), stimulates the in-
duction of Th1 cells (36), and in addition inhibits Th2 cell
development (37). On the other hand, IL-4 is required for
the differentiation of naive T cells into Th2 effector cells
(38–41), and no Th2 responses are generated in IL-4–defi-
cient mice (42, 43) or STAT6-deficient mice (44–46).
Unlike from Th1 and Th2 cells with their restricted abil-
ity to produce particular cytokines, V
 
a
 
14 NKT cells pro-
duce both IFN-
 
g
 
 and IL-4 after stimulation with either
anti-CD3 (47, 48) or 
 
a
 
-GalCer (13). Since IL-4 and IFN-
 
g
 
have an opposite effect on Th2 cell differentiation, exten-
sive studies on the role of NKT cells have been performed.
However, this issue remains controversial. Thus, although
Yoshimoto et al. reported evidences indicating an impor-
tant role for NKT cell derived IL-4 in Th2 cell differentia-
tion (49, 50), recent reports by other investigators indicated
that CD1-deficient or 
 
b
 
2-microglobulin–deficient mice
with few NKT cells produced normal levels of antigen-
specific IgE (17, 51–53). In view of this situation, we de-
cided to reexamine the role of V
 
a
 
14 NKT cells on Th2
differentiation and subsequent IgE antibody responses by
using V
 
a
 
14 NKT cell–deficient mice generated by gene
targeting.
We demonstrate in this report that V
 
a
 
14 NKT cells are
not required for IgE responses induced by OVA-immuni-
zation or 
 
Nippostrongylus brasiliensis 
 
(Nb)
 
 
 
infection. How-
ever, antigen-specific IgE production was significantly
suppressed when V
 
a
 
14 NKT cells were activated with
 
a
 
-GalCer. These results indicate that Th2 cell differentia-
tion and subsequent IgE responses can be negatively regu-
 
lated by IFN-
 
g
 
 produced by ligand-activated V
 
a
 
14 NKT
cells.
 
Materials and Methods
 
Mice.
 
V
 
a
 
14 NKT-deficient (NKT-KO) mice were estab-
lished by specific deletion of the J
 
a
 
281 gene segment with ho-
mologous recombination and aggregation chimera techniques
(12). In these mice, only V
 
a
 
14 NKT cells are missing and other
lymphoid populations, such as T, B, and NK cells remain intact.
The V
 
a
 
14 NKT-KO mice were backcrossed 7 times with
C57BL/6 (B6) mice. V
 
a
 
14 NKT (RAG
 
2/2
 
 V
 
a
 
14Tg V
 
b
 
8.2Tg)
mice with a B6 background were established by mating RAG
 
2/2
 
V
 
b
 
8.2Tg mice and RAG
 
2/2
 
 V
 
a
 
14Tg mice as previously de-
scribed (12, 13). In the V
 
a
 
14 NKT mice, because they lacked
gene rearrangement of endogenous TCR-
 
a/b
 
 genes, only trans-
genic TCR-
 
a/b
 
 (V
 
a
 
14Tg and V
 
b8.2Tg) are expressed, and re-
sulted in preferential development of Va14 NKT cells with no
detectable number of conventional T cells. IFN-g–deficient mice
were provided by Y. Iwakura (Institute of Medical Science, the
University of Tokyo, Tokyo, Japan) (54). Pathogen-free B6, (B6 3
BALB/c)F1 mice were purchased from Japan SLC Inc. All mice
used in this study were maintained in specific pathogen-free con-
ditions and used at 8–12 wk of age.
Immunofluorescent Staining and Flow Cytometry Analysis.
Freshly prepared splenocytes were suspended in PBS supple-
mented with 2% FCS and 0.1% sodium azide. In general, 106
cells were preincubated with 2.4G2 (PharMingen) to prevent
nonspecific binding of mAbs via FcR interactions, and then cells
were incubated on ice for 30 min with FITC-conjugated anti–
TCR-a/b (H57-597-FITC) and PE-conjugated anti-NK1.1
(PK136-PE) as previously described (12). Both reagents were
purchased from PharMingen. Flow cytometry analysis was per-
formed on Epics-Elite (Coulter Electronics).
Treatment with Anti-CD3 mAb and a-GalCer (KRN7000).
Wild-type and NKT-KO mice were injected intravenously with
1.5 mg of anti-CD3 mAb (PharMingen, 145-2C11) in 200 ml
PBS. 90 min after the anti-CD3 treatment, splenocytes were sep-
arated and cultured (5 3 106 cells/ml) in 6-well culture plates
(Falcon 3046) for 1 h at 378C, and then the supernatants were
collected and subjected to ELISA for IL-4. For activation of
Va14 NKT cells with a-GalCer, mice were intraperitoneally in-
jected with a-GalCer (100 mg/kg) or control vehicle as previ-
ously described (13). a-GalCer (KRN7000) was provided by Ki-
rin Brewery Co. The a-GalCer stock solution did not contain
detectable endotoxins, as determined by Limulus amebocyte assay
(sensitivity limit 0.1 ng/ml) as previously described (55). The
stock solution (220 mg/ml) was diluted in control vehicle, and a
mouse received 2 mg of a-GalCer. Whole spleen cells were pre-
pared 0.5, 1, 2, and 24 h after the injection and washed exten-
sively with ice-cold PBS, and the amounts of IFN-g were deter-
mined by RT-PCR. In some experiments, sera were taken 2 and
24 h after the a-GalCer injection and subjected to ELISA for
IFN-g.
ELISA for Measurement of Cytokine Concentration. IFN-g
(EN2604-50; Endogen) and IL-4 (EN2601-80; Endogen) con-
centrations in sera or the culture supernatants were measured by
ELISA as previously described (13).
Measurement of IFN-g Transcripts. The amounts of IFN-g
transcript were determined with reverse transcriptase (RT)-PCR.
Total cellular RNA from splenocytes was prepared using TRI-
ZOL (GIBCO BRL, 15596-018) according to a manufacturer’s
protocol. 10 mg of RNA were reverse transcribed in 20 ml of785 Cui et al.
mixture by using oligo dT primers, and 1 ml of reaction mixture
was subjected to PCR as previously described (10).
Nippostrongylus brasiliensis Infection and OVA Immunization.
Mice were subcutaneously infected with 750 third stage larvae of
Nb (56). 3 and 6 wk after infection, the mice were immunized
with 10 mg DNP-conjugated Nippostrongylus adult antigen
(DNP-Nb) mixed with 2 mg of alum [Al(OH)3; Wako Chemi-
cal. Co.] as an adjuvant.
For OVA immunization, 10 mg of OVA or DNP-OVA were
mixed with 5 mg of alum. The immunized mice were treated in-
traperitoneally with a-GalCer (100 mg/kg) or control vehicle on
days 1, 5, and 9. 4 wk later, mice were challenged with 10 mg of
DNP-OVA in alum. Serum was collected 2 and 3 wk after pri-
mary OVA immunization, and 1 wk after the secondary chal-
lenge. IgE production was determined by passive cutaneous ana-
phylaxis (PCA) and ELISA, and the production of IgG1 and
IgG2a was determined by ELISA.
ELISA for Measurement of Antibody Concentration. The total
serum IgE level was determined by ELISA as previously de-
scribed (57). In brief, 96-well plates (Dynatech) were coated with
an anti–mouse IgE mAb (6HD5), then plates were blocked with
1% BSA. After application of serum samples and standards (anti-
DNP IgE mAb, SPE-7; Seikagaku Kogyo), biotinylated anti–
mouse IgE mAb (HMK-12) was added for 30 min, followed by
addition of avidin-peroxidase. The plates were washed with PBS
containing 0.5% Tween 20. The substrate solution (ABST and
H2O2) was added, and the reaction was stopped with citrate and
read at 450 nm with an ELISA reader (Bio-Rad 550).
For detecting anti-DNP IgG1 or IgG2a antibody, 96-well
plates were coated with DNP-BSA. After blocking, standard
anti-DNP IgG1 mAb (NKIgG1), standard anti-DNP anti-IgG2a
mAb (DO5-1C4), and samples were added. For second anti-
bodies, an affinity-purified rabbit anti–mouse IgG1-peroxidase
(Zymed) or a rabbit anti–mouse IgG2a-peroxidase (Zymed) was
used, respectively.
Measurement of IgE Antibody Production by PCA Reaction.
Anti-DNP-specific and anti-OVA-specific IgE antibody was de-
tected by PCA reaction in rats as previously described (57). Serial
dilution of serum was injected intradermally into normal Wistar
rats. After a 24-h sensitization period, OVA or DNP-BSA was
intravenously injected with Evans Blue. The reaction was exam-
ined at 30 min after the challenge. Titers were expressed as the
highest dilution eliciting a reaction.
In Vitro Th1/Th2 Cell Induction Culture. Naive CD44lowCD41
T cells from (B6 3 BALB/c)F1 or Ly5.1 B6 spleen were pre-
pared as follows: splenocytes were incubated with a mixture of
anti-CD8 (53-6.72), anti-NK1.1 (PK136), and anti-CD44 (IM7)
mAbs (PharMingen). The treated cells were washed, then incu-
bated on plastic dishes coated with goat anti–mouse IgGs (which
cross-react with rat IgG, including 53-6.72, PK136, and IM7).
The nonadherent cells were used as naive CD44lowCD41 T cell
population. Contaminations of CD44high cells, NK1.11 cells, or
CD8 T cells were ,3% in either marker. The CD44lowCD41 T
cells (1.5 3 106) were stimulated with immobilized anti–TCR-
a/b mAb in the presence of IL-2 (30 U/ml) and graded doses of
IL-4 to induce Th1 and Th2 cells in vitro as previously described
(58, 59). After stimulation for 2 d, the cells were harvested and
cultured for an additional 3 d without anti-TCR stimulation in
the presence of IL-2 (30 U/ml). Intracellular staining of IL-4 and
IFN-g was performed as previously described (58, 59). Biotiny-
lated anti-Kd or anti-Ly5.1 mAbs (PharMingen) and allophycocy-
anin-conjugated avidin (The Jackson Laboratory) were used for
identifying responding naive T cells from (B6 3 BALB/c)F1 and
Ly5.1 B6 mice, respectively. Va14NKT cells from a-GalCer–
injected Va14 NKT mice with a normal Ly5.2 background were
added to the induction culture. The cell number of Va14NKT
cells added was adjusted by prestainings of an aliquot of NKT
spleen cells with anti–TCR-b and anti-NK1.1 mAbs. Where in-
dicated, anti–IFN-g mAb (5 mg/ml; PharMingen) was added in
the Th1/Th2 cell differentiation culture.
Results
The goal of this study was to clarify the effector mecha-
nisms of Va14 NKT cell regulation of Th2 cell differentia-
tion and the subsequent induction of IgE responses. To ad-
dress this question, we used NKT-KO mice in which the
development of Va14 NKT cells was dramatically inhib-
ited (reference 12, Fig. 1 A), and which produced essen-
tially no primary IL-4 upon anti-CD3 stimulation (Fig. 1
B) or a-GalCer-treatment (data not shown).
No Impairment in the IgE Responses Induced by Nb Infection
and OVA Immunization in NKT-KO Mice. NKT-KO
mice with B6 background were infected with Nb, and 3 wk
later the mice were immunized with DNP-conjugated Nb
in alum for the induction of DNP-specific IgE production.
To our surprise, the levels of total IgE and DNP-specific
IgE detected in wild-type mice were almost identical to
those observed in NKT-KO mice (Fig. 2 A). In addition,
DNP-specific IgG1 and IgG2a levels in NKT-KO mice
were comparable to those observed in the wild-type mice
(Fig. 2 A, right, middle and bottom). We also examined
the involvement of Va14 NKT cells in the regulation of
IgE response induced by OVA, a conventional protein an-
Figure 1. Primary IL-4 production in NKT-deficient mice. (A) TCR-
b/NK1.1 staining profiles of spleen cells from wild-type (WT) and NKT-
deficient mice (NKT-KO). The percentages of TCR-b1/NK1.11 NKT
cells are shown in each panel. (B) IL-4 production of spleen cells from
NKT-KO mice after intraperitoneal injection of anti-CD3 mAb. 90 min
after the injection of 1.5 mg of anti-CD3 mAb (black bars) or control
hamster Igs (white bars), splenocytes were prepared and cultured in vitro
for 60 min (5 3 106 cells/ml). The amount of IL-4 released in culture su-
pernatant was determined by ELISA. Three mice were used in each
group.786 Suppression of IgE Response by Va14 NKT Cells
tigen. NKT-KO mice were immunized with OVA in
alum, and OVA-specific IgE and IgG1 productions were
measured. Primary and secondary responses showed no sig-
nificant differences in the serum antibody levels detected in
wild-type and NKT-KO mice (Fig. 2 B). These results in-
dicated that Va14 NKT cells were not required for anti-
gen-specific IgE responses induced by either Nb infection
or OVA immunization.
Effect of a-GalCer Treatment on IgE, IgG1, and IgG2a Re-
sponses Induced by OVA Immunization. It is well docu-
mented that IgE and IgG1 responses are mediated by anti-
gen-specific Th2 cells, and that IgG2a responses depend on
Th1 cells (60). Consequently, we induced a specific activa-
tion of Va14 NKT cells in vivo by using a-GalCer, and
the antigen-specific IgE, IgG1, or IgG2a production was
assessed. As shown in Fig. 3 A, anti-DNP IgE response in-
duced by DNP-OVA immunization was dramatically re-
duced in wild-type mice after a-GalCer injection, whereas
no inhibition was observed in NKT-KO mice. Some in-
hibitory effect was also observed in DNP-specific IgG1 re-
sponse in wild-type mice (Fig. 3 B). In contrast, anti-
DNP-IgG2a responses were not reduced, but rather
slightly enhanced in wild-type mice (Fig. 3 C). These re-
sults suggested that the stimulation of Va14 NKT cells
with  a-GalCer resulted in the suppression of OVA-specific
Th2 responses with a subsequent decrease in IgE and IgG1
production while maintaining an intact or enhanced Th1-
dependent IgG2a production.
Involvement of IFN-g in the a-GalCer–induced Suppression
of IgE Responses. Since IFN-g has a potent inhibitory ef-
fect on Th2 responses (37), we next assessed serum levels of
IFN-g in B6 mice after in vivo treatment with a-GalCer,
which activates Va14 NKT cells. Spleen cells were pre-
pared 0.5, 1, 2, or 24 h after intravenous administration of
a-GalCer, and IFN-g transcripts were detected by RT-
PCR (Fig. 4 A). Serum levels of IFN-g were also assayed
by ELISA (Fig. 4, B and C). IFN-g transcripts were de-
tected within 2 h after a-GalCer injection in wild-type
mice, whereas no transcript was detected in NKT-KO
mice. Essentially similar results were obtained by the assess-
ment of serum IFN-g (Fig. 4, B and C). These results
strongly suggested that a large amount of IFN-g was pro-
duced by Va14NKT cells after a-GalCer treatment in
vivo.
Next, we used IFN-g–deficient mice and examined
whether the a-GalCer–induced IgE suppression was de-
tected or not. IFN-g–deficient mice were immunized with
DNP-OVA in alum, and primary IgE and IgG1 responses
Figure 2. IgE responses induced by Nb
infection and OVA immunization in NKT-
KO mice. (A) Total serum IgE, antigen-spe-
cific IgE, IgG1, and IgG2a production in
NKT-KO mice induced by Nb infection
and DNP-Nb challenge. NKT-KO mice
were infected with Nb (wk 0) and 3 wk
later were immunized with DNP-conju-
gated Nb in alum in order to induce DNP-
specific responses. The serum levels of total
IgE, anti-DNP-IgG1, and anti-DNP-IgG2a
were determined by ELISA. The anti-DNP-
specific IgE levels were assessed by PCA re-
action. Five mice were used in each group.
The mean 6 SD is shown. (B) Antigen-spe-
cific IgE and IgG1 production in NKT-KO
mice induced by OVA immunization.
NKT-KO mice were immunized with OVA
in alum (wk 0) and 3 wk later were chal-
lenged with OVA. The serum concentra-
tions of anti-OVA-specific IgE and anti-
OVA-specific IgG1 were shown. Five mice
were used in each group. The mean 6 SD is
shown.
Figure 3. Serum concentration of DNP-specific
IgE, IgG1, and IgG2a in NKT-KO mice treated
with a-GalCer. NKT-KO mice were immunized
with DNP-OVA with alum. 3 wk later, mice were
challenged with DNP-OVA in alum. The sera
were taken 7 d after the challenge. In addition,
mice were treated with a-GalCer (black bars) or
vehicle (white bars) on days 1, 3, and 9. Serum con-
centrations of anti-DNP-IgE, anti-DNP-IgG1, and
anti-DNP-IgG2a were determined by ELISA or
PCA. Each group consisted of five mice. The mean 6
SD is shown.787 Cui et al.
and secondary IgE responses were assessed (Fig. 5). As we
expected, no suppression in the production of IgE was
observed in either primary or secondary responses in IFN-
g–deficient mice. In addition, IgG1 response was not im-
paired. Va14 NKT cells in IFN-g–deficient mice pro-
duced an equivalent level of IL-4 upon stimulation with
a-GalCer (data not shown). Thus, it is most likely that the
suppressive effect on IgE production is mediated by IFN-g
produced by Va14 NKT cells.
Inhibition of Th2 Cell Differentiation by Activated Va14
NKT Cells Detected in an In Vitro Th1/Th2 Cell Induction
Culture System. The results obtained thus far favor the
notion that IFN-g produced by activated Va14 NKT cells
inhibits Th2 cell differentiation, and results in suppression
of antigen-specific IgE production. Consequently, the role
of ligand-activated Va14 NKT cells on Th2 cell differenti-
ation was examined more precisely through the use of an in
vitro induction culture system (58, 59). Naive CD4 T cells
obtained from (B6 3 BALB/c)F1 mice or Ly5.1 B6 mice
were stimulated with immobilized anti-TCR mAb in the
presence of IL-4 to allow Th1 and Th2 cell differentiation
in vitro. Several doses of Va14 NKT cells from a-GalCer–
treated Va14 NKT mice with normal Ly5.2 B6 back-
ground were added in the induction culture, and the intra-
cellular production of IFN-g and IL-4 in Kd-positive T
cells or Ly5.1 T cells was assessed as shown in Fig. 6. No
detectable alloreactivity of Va14 NKT cells from NKT
mice against (B6 3 BALB/c)F1 splenic T cells was de-
tected (data not shown). The numbers of T cells harvested
were similar in these different culture conditions (data not
shown). In this culture system, an IL-4 dose-dependent in-
crease in the generation of Th2 cells was observed (Fig. 6,
A and B, top). However, the addition of activated Va14
NKT cells in the induction culture inhibited IL-4–produc-
ing Th2 cell differentiation in a cell–dose-dependent man-
ner (Fig. 6, middle and bottom). In addition, the number
of IFN-g producing Th1 cell differentiation was signifi-
cantly enhanced in the presence of activated Va14 NK T
cells. The addition of nonactivated Va14 NKT cells from
vehicle-treated Va14 NKT mice did not have any effect
on Th1/Th2 cell differentiation (data not shown). These
results clearly indicated that Th2 cell differentiation was in-
hibited by the addition of preactivated Va14 NKT cells.
Finally, we addressed whether the inhibition of Th2 cell
differentiation induced by ligand-activated Va14 NKT
cells was mediated by IFN-g. Anti–IFN-g mAb was added
to the induction cultures containing responder CD4 T cells
and activated Va14 NKT cells. As shown in Fig. 6 C, the
inhibition of Th2 cell differentiation induced by Va14
NKT cells was completely rescued by the addition of anti–
IFN-g mAb. Thus, similar to the mechanisms governing
IgE suppression in in vivo experimental system (Fig. 5),
IFN-g appeared to be an effector molecule for the inhibi-
tion of Th2 cell differentiation induced by activated Va14
NKT cells in vitro.
Figure 4. IFN-g production in NKT-KO mice
after a-GalCer treatment. (A) Whole spleen cells
were prepared at the indicated times after intraperi-
toneal injection of a-GalCer, and total RNA was
extracted. IFN-g mRNA in the splenocytes were
determined with RT-PCR. Serum concentrations
of IFN-g were assessed 2 (B) and 24 (C) h after the
treatment with a-GalCer (black bars) or vehicle
(white bars). Each group consisted of three samples.
Figure 5. Serum concentration of DNP-specific IgE and IgG1 in IFN-
g–KO mice treated with a-GalCer. Serum levels of anti-DNP-IgE and
anti-DNP-IgG1 were determined 3 wk after DNP-OVA immunization.
Serum levels of anti-DNP-IgE at 1 wk after secondary challenge with
DNP-OVA were also determined. Serum levels of anti-DNP-IgE were
determined by PCA. Three mice were used in each group. The mean 6
SD is shown.788 Suppression of IgE Response by Va14 NKT Cells
Discussion
In this report, we describe in vivo studies that demon-
strate that Va14 NKT cells are not required for antigen-
specific IgE responses induced by Nb infection and OVA
immunization (Fig. 2). This conclusion is supported by in
vitro studies indicating that the addition of activated Va14
NKT cells to in vitro Th1/Th2 cell differentiation cultures
resulted in the inhibition rather than the induction of Th2
cell differentiation (Fig. 6). These results are in agreement
with those reported by others (17, 51–53). Smiley et al. re-
ported that the anti-IgD-induced IgE responses were not
impaired in CD1-deficient mice in which NKT cell devel-
opment is largely inhibited (17). Similarly, b2-microglobu-
lin–dependent T cells, including NKT cells and conven-
tional CD8 a/b T cells, were reported to be nonessential
for Th2 responses induced by immunization with different
protein antigens or after infection with certain microorgan-
isms (51–53). However, in contrast, Yoshimoto et al. re-
ported that b2-microglobulin–dependent T cells were im-
portant for anti-IgD–induced IgE production, and that
NK1.11 thymocytes restored the defect of anti-IgD–induced
IgE production in b2-microglobulin–deficient mice (49,
50). Regardless of the reasons that may explain the discrep-
ancy with the results obtained with b2-microglobulin–
deficient mice, our data clearly demonstrate that Va14 NKT
cells are dispensable for IgE responses, at least those in-
duced by Nb infection and OVA immunization. In addi-
tion, our results suggest that Va14 NKT cells are not the
major cell source of IL-4 that is required for Th2 cell dif-
ferentiation. Although several cell types have been pro-
posed as candidates for the source of IL-4 that initiates cer-
tain Th2 responses (61–66), the precise mechanisms of how
these cells are activated and produce IL-4 leading to Th2
cell differentiation remain to be elucidated.
More interestingly, by using a-GalCer that is a specific
stimulating ligand for Va14 NKT receptor, we found a
unique regulatory role of Va14 NKT cells on Th2 cell dif-
ferentiation. We observed a selective in vivo suppression of
IgE production in mice treated with a-GalCer during
OVA priming or Nb infection. A mild but reproducible
suppression of the IgG1 response was also observed (Fig.
3). In contrast, IgG2a response was not suppressed and in
fact a slight enhancement was detected, suggesting an inhi-
bition in the generation of antigen-specific Th2 cell differ-
entiation. Importantly, Va14 NKT cells produced large
amounts of IFN-g in the serum when mice were treated
with a-GalCer (Fig. 4), and the suppression of IgE was not
detected in either NKT-KO or IFN-g–deficient mice (Figs. 3
and 5). Thus, it is most likely that the selective IgE suppres-
Figure 6. In vitro anti-TCR mAb–induced Th1/Th2 cell differentiation in the pres-
ence of ligand-activated Va14 NKT cells. CD41 naive T cells (1.5 3 106) from (B6 3
BALB/c)F1 (A and C) or Ly5.1 B6 (B) mice were stimulated with immobilized anti-
TCR mAb (H57-597; 30 mg/ml) in the presence of 1 or 10 U/ml of recombinant IL-4.
Graded doses of activated Va14 NKT cells from NKT mice with a-GalCer treatment
were added at the beginning of the induction culture. Anti–IFN-g mAb (5 mg/ml) was
added to the induction culture. Yields of the cells were similar in these culture condi-
tions. Intracellular staining profiles of IL-4 and IFN-g of electronically gated Kd-bearing
T cells (A and C) or Ly5.1 T cells (B) are shown. The percentages of cells present in each
area are indicated.789 Cui et al.
sion observed in a-GalCer–treated mice was due to an im-
paired Th2 cell differentiation induced by large amounts of
IFN-g secreted from activated Va14 NKT cells. Consis-
tent with this, the inhibition of Th2 cell differentiation in-
duced by activated Va14 NKT cells appeared to be an
IFN-g–mediated consequence (Fig. 6 C). A similar sup-
pressive effect on IgE production by IFN-g was reported in
several other experimental systems (67–72). IFN-g pro-
duced by g/d T cells suppressed IgE responses in OVA-spe-
cific responses (71) and cutaneous contact sensitivity system
(72). In addition, since IFN-g is known to be produced by
CD81  a/b-TCR T cells, a possible inhibitory role for
these cells in the regulation of IgE responses has been pro-
posed (73).
Recently, Kitamura et al., in collaboration with us, re-
ported a study addressing the role of IL-12 in the produc-
tion of IFN-g from a-GalCer–activated NKT cells (74).
The majority of IFN-g production induced by a-GalCer
and dendritic cells was found to be inhibited by the addi-
tion of anti–IL-12 mAb to the culture, indicating the in-
volvement of IL-12 in the IFN-g production. IL-12 ap-
peared to be produced by dendritic cells only when they
interacted with a-GalCer–activated Va14 NKT cells. The
IL-12 in turn enhanced the IFN-g production of the acti-
vated Va14 NKT cells. In addition, transcriptional upregu-
lation of IL-12 receptor was detected after a-GalCer ad-
ministration (74). Thus, it is conceivable that IL-12 plays a
significant role for the IFN-g–mediated suppressive effect
on IgE responses.
Our results suggest that, upon stimulation with certain
ligands such as glycosylphosphatidylinositol-anchored pro-
tein (21) expressed on parasites or other microorganism,
Va14 NKT cells become IFN-g–producing cells, leading
to the inhibition of Th2 cell differentiation and suppression
of IgE responses. In addition, our recent experiments have
suggested that a bacteria-derived material, LPS, is able to
stimulate Va14 NKT cells to produce a large amount of
IFN-g (data not shown). Clearly, further analyses are re-
quired for addressing the physiological consequences of
Va14 NKT cell–mediated regulation of IgE response.
However, it is noteworthy that the successful activation of
Va14 NKT cells and subsequent inhibition of Th2 re-
sponses, as described in this report, may open new avenues
for research aimed at developing treatment for Th2-depen-
dent diseases, such as systemic autoimmune diseases,
chronic graft versus host diseases, and allergic diseases.
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